紫杉醇/卡铂/二甲双胍对比紫杉醇/卡铂/安慰剂作为可测量III期或IVA期、IVB期或复发性子宫内膜癌初始治疗的随机II/III期研究:一项NRG肿瘤学/GOG研究
该II/III期随机试验将448例晚期或复发性子宫内膜癌患者随机分配至紫杉醇/卡铂联合二甲双胍(850 mg每日两次)或安慰剂组,二甲双胍或安慰剂在化疗后继续作为维持治疗直至疾病进展。中期分析因无效于2018年2月1日停止入组,加用二甲双胍组死亡风险略高(HR=1.088;90% CI 0.803至1.475),无进展生存HR=0.814(90% CI 0.635至1.043),研究提前终止。
要点
- 加用二甲双胍未显著改善无进展生存(HR=0.814;90% CI 0.635至1.043)。
- 加用二甲双胍组死亡风险略高(HR=1.088;90% CI 0.803至1.475),研究因无效提前终止。
- 中位随访10个月、121例死亡时,安慰剂组中位总生存未确定,二甲双胍组为28个月。
核心结论
- 在紫杉醇/卡铂基础上加用二甲双胍未能充分降低无进展生存和总生存的风险比,不足以支持继续该试验。
研究设计与样本
- 随机II/III期试验,纳入化疗初治的III/IVA期(可测量疾病)及IVB期或复发性(可测量或不可测量疾病)子宫内膜癌患者,随机分配至紫杉醇/卡铂联合二甲双胍(850 mg每日两次)或紫杉醇/卡铂联合安慰剂组。
- 二甲双胍或安慰剂在完成紫杉醇/卡铂后继续作为维持治疗直至疾病进展。
- II期主要终点为无进展生存,III期主要终点为总生存,次要终点为客观缓解、缓解持续时间和毒性。
- 2014年3月17日至2017年12月22日期间共448例患者被随机分配至II/III期研究,数据冻结进行中期分析。
主要发现
- II期研究认为二甲双胍值得在III期研究中进一步考察。
- III期中期分析因无效于2018年2月1日停止入组。
- 加用二甲双胍组相比紫杉醇/卡铂方案死亡风险略高(HR=1.088;90% CI 0.803至1.475),足以提前终止研究。
- 无进展生存的风险比为HR=0.814(90% CI 0.635至1.043)。
- 中位随访10个月、121例死亡时,安慰剂组中位总生存未确定,二甲双胍组为28个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We evaluated the efficacy of the addition of the anti-diabetic drug metformin to standard-of-care paclitaxel and carboplatin (PC) in patients with advanced and recurrent endometrial cancer (EC). METHODS: In this phase II/III trial, EC patients with chemotherapy-naïve stage III/IVA (with measurable disease) and stage IVB or recurrent (with or without measurable disease) disease were randomly assigned to PC/metformin (850 mg BID) versus PC/placebo. Metformin or placebo was continued as maintenance therapy after completion of PC until disease progression. The primary endpoint of phase II was progression-free survival (PFS). The primary endpoint of phase III was overall survival (OS). Secondary endpoints were objective response, duration of response, and toxicity. RESULTS: From 3/17/2014 to 12/22/2017, 448 patients were randomized to phase II/III studies, and the data were frozen for interim analysis. The phase II study deemed metformin worthy of further investigation in the phase III study. The interim phase III analysis stopped accrual for futility on 2/1/2018. The addition of metformin to PC had a slightly higher hazard of death compared to the PC regimen (HR = 1.088; 90% CI 0.803 to 1.475), which was sufficient to close the study early. The PFS had (HR = 0.814; 90% CI 0.635 to 1.043). At a median follow-up of 10 months and 121 deaths, median OS was not determined and 28 months, on PC/placebo and PC/metformin, respectively. CONCLUSION: The hazard ratios for PFS and OS endpoints was not sufficiently decreased with the addition of metformin to PC to justify continuing the trial.
引用
- Bae-Jump VL, Sill MW, Gehrig PA, et al. A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study. Gynecol Oncol. 2025. PMID: 40056832. doi:10.1016/j.ygyno.2025.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。